FDA
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
-
-
-
-
-
-
-
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
-
326,122 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

